You are here: Industry Insights > Merck

News List

Merck’s KEYTRUDA monotherapy trial meets primary endpoint expressbpd
April 11, 2018
Merck Announces Key Three Phase KEYNOTE-042 Trial to Assess Merck's Anti-PD-1 Therapy KEYTRUDA as first-line therapy for locally advanced or metastatic non-small cell lung cancer Monotherapy
Merck’s Keytruda Grabs Another Late-Stage Clinical Win in Lung Cancer biospace
April 10, 2018
Merck & Co. is chalking up another clinical win for its potent checkpoint inhibitor Keytruda.
Incyte, Merck Provide Update Study of Epacadostat in Combination with KEYTRUDA americanpharmaceuticalreview
April 09, 2018
Incyte and Merck Announce the External Data Monitoring Committee (eDMC) to Review Key Phase 3 ECHO-301/KEYNOTE-252 Study Results for the Evaluation of Incyte's epacadostat in Combination with Merck's KEYTRUDA for Unresectable or Metastatic Melanoma Patien
Incyte and Merck Provide Update on Phase 3 Study of Epacadostat in Combination with KEYTRUDA® (pembrolizumab) in Patients with Unresectable or Metastatic Melanoma biospace
April 08, 2018
MSD announced today that the External Data Monitoring Committee has reviewed the results of a key Phase 3 ECHO-301/KEYNOTE-252 study evaluating KEYTRUDA® for the treatment of patients with unresectable or metastatic melanoma by Incyte epacadostat with Mer
ITRI teams up with Merck for drug manufacturing biospectrumasia
April 04, 2018
This project is expected to strengthen Taiwan, China’s biopharma sector by combining the R&D resources from ITRI with key technologies and advanced manufacturing processes from Merck to cultivate high-end professionals in Taiwan, China.
Merck as the best bioprocessing supplier in Asia biospectrumasia
March 29, 2018
For second consecutive year, Merck chosen as “Best Bioprocessing Supplier” by Asia-Pacific Bioprocessing Excellence Awards.
Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan biospace
March 28, 2018
Merck today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved SAKIGAKE's rapid generic name for its researcher tepotinib*
Roche’s Tecentriq hits mark in squamous NSCLC – how loud are Merck & Co.’s footsteps? firstwordpharma
March 23, 2018
Roche Tecentriq (atezolizumab) plus chemotherapy for prolonged progression-free survival (PFS) as a first-line treatment in the stage III IMpower 131 trial for squamous cell carcinoma non-small cell lung cancer (NSCLC)
FDA Grants Merck's Keytruda Priority Review for Cervical Cancer biospace
March 14, 2018
The U.S. Food and Drug Administration (FDA) accepted Merck & Company’s supplemental Biologics License Application and granted Priority Review for Keytruda (pembrolizumab) in advanced cervical cancer.
Immutep, Merck & Co. Enter Partnership contractpharma
March 13, 2018
Immutep Limited has entered into a clinical trial collaboration and supply agreement with Merck & Co.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page